12:26 PM EDT, 09/20/2024 (MT Newswires) -- AstraZeneca's ( AZN ) nasal spray flu vaccine FluMist was approved by the US Food and Drug Administration for self administration, according to a statement Friday.

The approval covers the vaccine's use to protect against influenza virus subtypes A and B in individuals between the ages of 2 and 49, the FDA said.

The FDA said FluMist was the first flu vaccine that does not need to be administered by a health care provider.

It was previously approved for use in individuals aged 5 through 49, and then expanded to include children between the ages of 2 and 5.

Price: 78.25, Change: -0.65, Percent Change: -0.82